Jamjoom Pharma Acquires Saudi OSD Production Facility from Pfizer

Jamjoom Pharma, a leading pharmaceutical company in the Middle East and Africa (MEA), announced the signing of a Facility Sale and Purchase Agreement with Pfizer Saudi Limited Company to acquire a pharmaceutical manufacturing facility located in King Abdullah Economic City (KAEC), Saudi Arabia.

The facility specializes in the manufacturing and packaging of oral solid dosage (OSD) pharmaceutical products and operates across the full production chain, supported by on-site quality control laboratories. The site represents an important addition to Jamjoom Pharma’s manufacturing network and is expected to enhance its production and operational capabilities.

This step aligns with Jamjoom Pharma’s long-term growth strategy and commitment to advancing local manufacturing capabilities in the Kingdom of Saudi Arabia, supporting national priorities around localization and industrial development. It further enhances regional supply resilience and contributes to expanding access to high-quality, affordable healthcare solutions for patients across the Middle East and Africa.

Commenting on the announcement, Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, said “This agreement marks an important milestone in our growth journey and reflects our commitment to strengthening our manufacturing capabilities within the Kingdom. We are focused on building a scalable platform that supports sustainable growth while maintaining the highest standards of quality and operational excellence.”